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Introduction
Loss-of-function mutations in the tumor suppressor neurofi-
bromin 1 (NF1) underlie the common familial cancer syndrome 
neurofibromatosis type 1 and promote the development of a vari-
ety of sporadic cancers including glioblastoma, melanoma, and 
non–small cell lung cancer (NSCLC) (1). The NF1 gene encodes 
a Ras GTPase–activating protein (RasGAP) (2, 3). Accordingly, 
excessive Ras signaling underlies the pathogenesis of NF1-mutant 
tumors (4). However, despite this insight, there are currently no 
effective treatments for any NF1-deficient or Ras-driven cancers.
Because NF1-mutant tumors are driven by excessive Ras sig-
naling, we and others have been evaluating Ras pathway inhibitors 
in a variety of tumor models (5–7). Fortunately, MEK inhibitors 
exhibit efficacy in mouse models of clinically important benign 
tumors associated with neurofibromatosis type 1, including ner-
vous system lesions known as neurofibromas as well as juvenile 
myelomonocytic leukemia (JMML) (6, 7), which has inspired the 
development of several clinical trials (ClinicalTrials.gov). Howev-
er, MEK inhibitors are ineffective the most common malignancy 
associated with neurofibromatosis type 1: malignant peripheral 
nerve sheath tumors (MPNSTs) (8). Approximately 70% of MPNST 
patients present with unresectable and/or metastatic disease, and 
conventional chemotherapy and radiation do not improve overall 
survival; therefore, developing a treatment for these tumors repre-
sents a response to an urgent unmet clinical need (9).
In MPNSTs, mTORC1 is the critical PI3K pathway effector, and 
mTORC1 suppression alone exerts cytostatic effects in human cell 
lines and animal models (5, 10). While effects are only cytostatic, 
mTORC1 inhibitors are surprisingly more potent than MEK inhibi-
tors, underscoring the importance of this pathway in this tumor type 
(11). Moreover, when combined with MEK inhibitors, mTORC1 
inhibitors trigger cell death and dramatic tumor regression in vivo 
(11). Nevertheless, because these 2 major pathways regulate so many 
fundamental biological processes, it may be challenging to identify 
an effective therapeutic window in humans using combined MEK/
mTORC1 inhibitors. Therefore, we have been working to iden-
tify new therapeutic targets within these pathways that, when sup-
pressed, may selectively affect cancer cells and spare normal tissue.
In the course of the studies presented here, we found that 
eIF4E, the limiting component of the eIF4F translation ini-
tiation complex, is a critical mTORC1 effector in MPNSTs. 
mTORC1 regulates eIF4E by phosphorylating and dissociating 
inhibitory eIF4E-binding proteins (4EBPs); however, eIF4E 
function is also controlled by phosphorylation at serine 209, 
which is exclusively mediated by the MAPK-interacting kinas-
es (MNKs) 1 and 2 (12–14). MNK phosphorylation of eIF4E has 
been shown to enhance the translation of several prooncogenic 
mRNAs, and several mechanisms by which this may occur have 
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eIF4E was phosphorylated in 9 of 10 and 4 of 5 tumors, respec-
tively (Figure 2, B and C). These observations suggest that the 
MNK/eIF4E signaling axis is activated in a high percentage of 
MPNSTs, warranting further investigation of the therapeutic 
potential of targeting this pathway.
Genetic suppression of MNK kinases cooperates with MEK inhibi-
tors to promote MPNST cell death. To evaluate the potential thera-
peutic effects of MNK inhibition, MNK2 and MNK1 were knocked 
down both independently and in combination. Suppression of 
either MNK2 or MNK1 alone led to a substantial but incomplete 
decrease in eIF4E phosphorylation that was completely lost when 
MNK1 and MNK2 were concomitantly suppressed, indicating that 
both highly related kinases contribute to eIF4E phosphorylation 
in these tumors (Figure 2D). We next examined the biological 
consequences of MNK suppression in the presence and absence 
of MEK inhibitors. Genetic ablation of either MNK1 or MNK2 
alone slightly inhibited proliferation, but killed cells when com-
bined with PD901 (Figure 2E). Concomitant suppression of MNK1 
and MNK2 further enhanced this cytotoxic response (Figure 2E). 
These results demonstrate that the combined suppression of MNK 
and MEK kinases potently kills MPNSTs, revealing potential ther-
apeutic strategies for these incurable malignancies.
Therapeutic agents that suppress MNK kinases cooperate 
with MEK inhibitors. To determine whether chemical inhibi-
tion of MNK kinases could recapitulate the effects of genetic 
suppression, we first utilized the MNK1 and MNK2 inhibitor 
CGP57380 (19). Similar to what occurs with genetic ablation of 
MNK1 and MNK2, CGP57380 inhibited eIF4ES209 phosphoryla-
tion in human MPNST cells (Figure 3A) and, on its own, partial-
ly suppressed proliferation (Figure 3B). Moreover, cells treated 
with a combination of CGP57380 and PD901 died (Figure 3B). 
Cercosporamide, a natural product that also inhibits MNK 
kinases (20), also suppressed eIF4ES209 phosphorylation (Fig-
ure 3C) and killed MPNST cells in a dose-dependent fashion 
when combined with PD901 (Figure 3D). Because CGP57380 
and cercosporamide are both tool compounds that are not 
being clinically developed, we investigated whether any other 
existing kinase inhibitors might suppress MNK and therefore 
could be more readily evaluated in vivo. Interestingly, the mul-
tikinase inhibitor merestinib/LY2801653, originally designed 
to suppress the receptor tyrosine kinase MET, has been shown 
to directly inhibit MNK1 and MNK2 kinases (21). Similarly, we 
found that the FDA-approved compound cabozantinib, a sec-
ond MET/multikinase inhibitor, also directly bound MNK1 and 
MNK2 with a Kd of 790 nM and 21 nM, respectively (Figure 3E), 
and suppressed eIF4ES209 phosphorylation in MPNSTs at even 
lower concentrations than CGP57380 (Figure 3F). Moreover, 
cabozantinib exerted a dose-dependent effect on eIF4ES209 
phosphorylation and MPNST cell death when combined with 
PD901 (Figure 3, G and H).
The therapeutic effects of cabozantinib/PD901 require the sup-
pression of MNK-induced eIF4ES209 phosphorylation. While these 
studies demonstrate that cabozantinib effectively inhibits MNK 
kinases, it was originally developed as an MET kinase inhibitor 
(22). Therefore, to independently examine the effects of MET 
suppression in MPNSTs, we evaluated the effects of the struc-
turally unrelated selective MET kinase inhibitor PF-04217903, 
been proposed (reviewed in ref. 13). Interestingly, studies have 
shown that while MNK kinases and eIF4E phosphorylation are 
dispensable for normal development and function, eIF4ES209 
phosphorylation is uniquely enhanced in several cancers and 
contributes to the development of prostate cancer and lympho-
ma (15–18). These findings demonstrate that the MNK/eIF4E 
signaling axis plays an important positive role in tumor develop-
ment. Nevertheless, it is currently unknown whether the MNK 
kinases are actually therapeutic targets and are required for the 
survival of existing tumors. We reasoned that MPNSTs repre-
sent a unique setting for evaluating the therapeutic potential of 
MNK inhibition, as the MNK/eIF4E signaling axis might pro-
vide an alternative targetable node in these tumors, obviating 
the need for broad mTORC1 suppression.
Using genetic and chemical approaches, we show that MNK 
kinases are important therapeutic targets in MPNSTs and that 
combined MNK and MEK suppression represents a promising new 
therapeutic strategy for treating these currently incurable malig-
nancies. Given that MNK kinases appear to be largely dispensable 
for normal cellular processes, a therapeutic index might be more 
readily achieved using combined MNK and MEK inhibitors. These 
studies also suggest that MNK inhibitors may represent an alter-
native to mTOR inhibitors in some settings.
Results
Combined eIF4E and MEK suppression kills MPNSTs. We previ-
ously showed that mTORC1 is critical for the proliferative and 
tumorigenic properties of NF1-mutant MPNSTs (5, 10). More-
over, when mTORC1 inhibitors are combined with MEK inhibi-
tors, human MPNST cells die and tumors regress in a well-
characterized genetically engineered MPNST model (Figure 
1A and ref. 11). Because eIF4E has been shown to be a critical 
downstream effector of mTORC1, we investigated whether sup-
pression of eIF4E was sufficient to recapitulate the effects of 
mTORC1 inhibition in this tumor type. Notably, RNAi-mediated 
suppression of eIF4E alone exerted cytostatic effects and inhib-
ited both proliferation and growth in soft agar in human (Figure 
1, B–D) and mouse (Figure 1E) MPNST cell lines, thus mimick-
ing the effects of mTOR inhibitors as single agents (Figure 1A 
and ref. 11). However, when combined with the MEK inhibitor 
PD-0325901 (PD901), eIF4E suppression triggered cell death 
(Figure 1, F and G). These results demonstrate that eIF4E is a 
critical effector in NF1-mutant MPNSTs and that eIF4E sup-
pression can cooperate with MEK inhibitors and substitute for 
mTORC1 suppression in this therapeutic setting.
The MNK/eIF4E signaling axis is activated in human and 
mouse MPNSTs. While mTORC1 activates eIF4E by phosphory-
lating and dissociating inhibitory 4EBP proteins, eIF4E func-
tion is also enhanced by phosphorylation at serine 209, which 
is exclusively regulated by MNK1 and MNK2 (reviewed in ref. 
13). To determine whether MNK/eIF4E signaling was activated 
in MPNSTs, we evaluated the phosphorylation status of eIF4E at 
serine 209 in human and mouse MPNSTs. Immunoblots using 
a phosphospecific antibody demonstrated that eIF4E is hyper-
phosphorylated at serine 209 in human and mouse MPNST 
cells compared with normal cells (Figure 2A). Analysis of pri-
mary human and mouse tumor tissue further demonstrated that 
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Figure 1. eIF4E is a critical mTORC1 effector in MPNSTs. (A) (Left) Immunoblots of p-ERK, 4EBP1, and p-S6 in S462 treated with 200 nM INK128 (an mTOR 
kinase inhibitor) and 750 nM PD901 (a MEK inhibitor) for 24 hours. (Right) Change in cell number of S462 cells treated with above concentrations of INK128 or 
PD901 alone or in combination. Graph represents the average log2 of fold change in cell number 72 hours after treatment relative to time 0 (mean ± SD, n = 3). 
Note that –1 on the y axis corresponds to a 50% decrease in cell number. (B) Immunoblot of eIF4E (left) and fold change in cell number on days 2 and 3 relative 
to day 0 (right) and of S462 cells stably expressing 2 unique shRNAs against EIF4E (shEIF4E_1 and shEIF4E_2) or shCNT (mean ± SD, n = 3). (C) Number of 
colonies formed in soft agar by S462 cells expressing shCNT, shEIF4E_1, or shEIF4E_2 (mean ± SD, n = 4, 1-way ANOVA followed by Bonferroni’s multiple com-
parisons test). (D) eIF4E levels (left) and fold change in cell number after 72 hours (right) of 90-8TL cells expressing shEIF4E_1, shEIF4E_2, or shCNT (mean ± 
SD, n = 3, 1-way ANOVA followed by Bonferroni’s multiple comparisons test). (E) Number of soft agar colonies formed by CM173 cells (mouse MPNST) express-
ing shCNT or 2 independent shRNAs against Eif4e (shEif4e_3 and shEif4e_4) (mean ± SD, n = 3, 1-way ANOVA followed by Bonferroni’s multiple comparisons 
test). (F) Levels of eIF4E and p-ERK in S462 cells stably expressing shCNT, shEIF4E_1, or shEIF4E_2 treated with 750 nM PD901 for 24 hours. (G) Change in cell 
number of S462 shCNT, shEIF4E_1, or shEIF4E_2 cells treated with 750 nM PD901 or a vehicle control. Graph represents the average log2 of fold change in cell 
number 72 hours after treatment with PD901 relative to time 0 (mean ± SD, n = 3). Experiments were conducted at least 3 times for validation.
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genetic ablation of AXL or VEGFR2 had no effect on the survival 
or proliferation of cells alone or when combined with PD901 
(Figure 4, C and D). Importantly, as observed with MET suppres-
sion, inhibition of these cabozantinib targets also had no effect 
on eIF4E phosphorylation (Figure 4, A and C), indicating cabo-
zantinib-mediated suppression of eIF4E phosphorylation occurs 
solely through direct MNK inhibition as opposed to downregu-
lation of upstream kinases that might converge on MNK1 and 
MNK2. Collectively, these genetic and chemical studies demon-
strate that (a) MNK suppression is sufficient to cooperate with 
MEK inhibitors to kill NF1-mutant MPNSTs, (b) several structur-
ally unrelated agents that directly suppress MNK kinase activity 
which did not suppress eIF4E phosphorylation (Figure 4A and 
ref. 23). PF-04217903 effectively suppressed MET phosphoryla-
tion in MPNST cells, but did not significantly affect proliferation 
(Figure 4, A and B). Moreover, combined PF-04217903/PD901 
did not trigger cell death or promote further proliferative sup-
pression compared with PD901 alone (Figure 4B). Other major 
targets of cabozantinib include VEGFR2, AXL, and c-KIT kinas-
es. Immunoblot analysis revealed that c-KIT is not expressed in 
these MPNST cells (data not shown). We therefore investigated 
whether suppression of AXL or VEGFR2 might be mediating the 
observed cytotoxicity. Unlike MNK suppression, which was suf-
ficient to kill MPNST cells in the presence of PD901 (Figure 2E), 
Figure 2. MNK kinases are frequently activated in MPNSTs, and genetic ablation triggers cell death when combined with MEK inhibitors. (A) (Left) 
Immunoblot using a phospho-specific (S209) eIF4E antibody of lysates from normal human fibroblasts (IMR90) and MPNST cells (S462) and (Right) 
mouse MPNST cell lines (1A50 and 2629_C). (B) eIF4E phosphorylation levels in lysates from primary human MPNSTs. (C) Levels of eIF4E phosphoryla-
tion in primary mouse MPNSTs. (D) (Left) MNK1 and p-eIF4E levels following expression of shMKNK2, transfection with siRNA against MKNK1 (siMKNK1), 
or combined shMKNK2 expression and siMKNK1 transfection in S462 cells. (Right) Because existing MNK2 antibodies are not specific, mRNA levels of 
MKNK2 in shMKNK2-expressing S462 cells are shown relative to nontargeting controls and normalized to GAPDH (mean ± SD, n = 3). (E) (Top) Change in 
cell number of S462 expressing shCNT or shMKNK2 transfected with siMKNK1 or siCNT and treated with 750 nM PD901 or a vehicle control (DMSO). Graph 
represents the average log2 of fold change in cell number 72 hours after treatment with PD901 relative to time 0 (mean ± SD, n = 3, 1-way ANOVA followed 
by Bonferroni’s multiple comparisons test). (Bottom) Levels of p-ERK in the corresponding cell lines following 24 hours of treatment with 750 nM PD901. 
Experiments repeated at least 3 times for validation.
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ylate eIF4E at S209 and because eIF4E is such a critical mTOR 
effector in these tumor cells. To confirm that the inhibition of 
eIF4ES209 phosphorylation was contributing to the therapeutic 
effects, we generated a previously described phosphomimetic 
mutant in which the serine at position 209 is substituted by an 
similarly cooperate with MEK inhibitors to kill these tumor cells, 
and (c) MET, AXL, and VEGFR2 suppression are not required 
nor sufficient to mediate the cytotoxic effects.
We initially began investigating MNK kinases as potential 
therapeutic targets in MPNSTs because they uniquely phosphor-
Figure 3. Multiple therapeutic agents that suppress MNK kinases cooperate with MEK inhibitors. (A) p-eIF4E and p-ERK1/2 levels in S462 cells 
treated with DMSO, 10 μM CGP57380, 750 nM PD901, or both inhibitors for 24 hours. (B) Change in cell number of S462 cells treated with 10 μM 
CGP57380 (CGP) or 750 nM PD901 alone or in combination. Graph represents the average log2 of fold change in cell number 72 hours after treatment 
relative to time 0 (mean ± SD, n = 3). (C) p-eIF4E and p-ERK1/2 levels in S462 cells treated with indicated concentrations of cercosporamide (Cerco.) 
alone or in combination with 750 nM PD901 for 24 hours. (D) Change in cell number of S462 cells treated with 10 μM or 20 μM cercosporamide or 750 
nM PD901 alone or in combination. Graph represents the average log2 of fold change in cell number 72 hours after treatment relative to time 0 (mean 
± SD, n = 3). (E) Binding of tagged MNK1 and MNK2 to immobilized ligand was measured in the presence of increasing cabozantinib. Tagged MNK 
kinases were quantified by real-time qPCR using previously described methods (26). Representative curves are shown. (F) Levels of p-eIF4E follow-
ing 24 hours of treatment with increasing concentrations of cabozantinib or 10 μM CGP57380. (G) p-eIF4E and p-ERK1/2 levels in S462 cells treated 
with 0.5 μM or 1 μM cabozantinib (Cabo) alone or in combination with 750 nM PD901 for 24 hours. (H) Change in cell number of S462 treated with the 
indicated concentrations of cabozantinib or 750 nM PD901 alone or in combination. Graph represents the average log2 of fold change in cell number 72 
hours after treatment relative to time 0 (mean ± SD, n = 3). Experiments repeated at least 3 times for validation.
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Figure 4. Cabozantinib cooperates with PD901 by suppressing MNK and eIF4E phosphorylation. (A) p-MET, p-eIF4E, and p-ERK1/2 levels in S462 cells 
24 hours after treatment with 1 μM PF04217903 and 750 nM PD901. (B) Change in cell number after treatment with 1 μM PF04217903 (PF903) and/or 750 
nM PD901. Graph represents the average log2 of fold change in cell number 72 hours after treatment relative to time 0 (mean ± SD, n = 3). (C) Axl, VEGFR-2, 
p-eIF4E, and p-ERK1/2 levels in S462s following transfection with siAXL, siKDR, or control siRNA (siCNT). (D) Change in cell number following transfection 
with siAXL, siKDR, or siCNT and treatment with 750 nM PD901. Graph represents the average log2 of fold change in cell number 72 hours after treatment 
relative to time 0 (mean ± SD, n = 3). (E) eIF4E levels in parental S462 cells or cells expressing exogenous Flag-HA–tagged (FHA) eIF4E WT or eIF4ES209D 
coexpressing shEIF4E_1 against endogenous eIF4E. (F) (Left) Change in cell number of FHA-WT eIF4E– and FHA-eIF4ES209D–expressing cells coexpressing 
shEIF4E_1 treated with 750 nM PD901 alone or in combination with 0.5 μM cabozantinib. Graph represents the average log2 of fold change in cell number 
72 hours after treatment relative to time 0 (mean ± SD, n = 3, t test). (Right) p-eIF4E and p-ERK1/2 levels in cells described above 24 hours after treat-
ment. (G) (Left) Levels of p-eIF4E in 90-8TL human MPNST cells relative to S462 cells. (Right) p-MET, p-eIF4E, and p-ERK1/2 levels in 90-8TL cells treated 
with 0.5 μM or 1 μM cabozantinib alone or combined with 1 μM PD901. (H) Change in cell number of 90-8TL cells treated with the indicated concentrations 
of cabozantinib or 1 μM PD901 alone or in combination. Graph represents the average log2 of fold change in cell number 72 hours after treatment relative to 
time 0 (mean ± SD, n = 3). Experiments repeated at least 3 times for validation.
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aspartic acid (eIF4ES209D) (18). Flag-HA–tagged eIF4ES209D and 
WT eIF4E were further engineered with sequential silent muta-
tions to prevent targeting by shEIF4E_1 and were ectopically 
expressed at physiological levels in MPNST cells together with 
shEIF4E_1 to suppress endogenous eIF4E expression (Figure 
4E). Notably, the cells expressing eIF4ES209D were significant-
ly less sensitive to cabozantinib/PD901 compared with cells 
expressing WT eIF4E (Figure 4, E and F). These observations 
demonstrate that the suppression of MNK-dependent eIF4E 
phosphorylation contributes to MPNST cell death triggered by 
combined cabozantinib/MEK inhibitors. Interestingly, while 9 
of 10 human and 4 of 5 mouse MPNSTs exhibited robust activa-
tion of the MNK/eIF4E signaling axis (Figure 2, B and C), we 
identified a human MPNST cell line that exhibited extremely 
low levels of eIF4E S209 phosphorylation (Figure 4G). While 
cabozantinib effectively suppressed MET phosphorylation in 
these cells, it had minimal effects on proliferation as a single 
agent and did not trigger cell death when combined with PD901 
(Figure 4, G and H), consistent with the importance of the MNK/
eIF4E signaling axis in conferring sensitivity.
Combined cabozantinib/PD901 treatment promotes tumor 
regression in vivo. Finally, to test the efficacy of combined MNK 
and MEK inhibition in vivo, we evaluated the effects of cabo-
zantinib and PD901 in a genetically engineered mouse MPNST 
model (24). Like human MPNSTs, tumors from these animals 
harbor compound mutations in Nf1 and Trp53. MPNSTs that 
develop in these animals are highly aggressive, and mice survive 
for an average of 10.7 days after tumors are detected, recapitu-
lating the aggressive nature of human tumors (24). As shown in 
Figure 5A, eIF4E was phosphorylated on serine 209 in mouse 
Figure 5. Combined cabozantinib and PD901 treatment induces tumor regression in vivo. (A) Levels of p-eIF4E and p-ERK1/2 in CM261 cells (mouse 
MPNST line) treated with 5 μM cabozantinib and 2 μM PD901 alone or in combination. (B) Graph depicting the change in cell number of mouse (CM261, left, 
and CM173, right) MPNST cells treated with 5 μM cabozantinib or 2 μM PD901 alone or in combination. Graph represents the average log2 of fold change in 
cell number 96 hours after treatment relative to time 0 (mean ± SD, n = 3). Experiments repeated at least 3 times for validation. (C) Waterfall plot depict-
ing change in tumor volume after 10 days of treatment with cabozantinib at 12.3 mg/kg/d (red bars) or in combination with PD901 at 1.5 mg/kg/d (orange 
bars) (P = 0.0022, Mann-Whitney U test, cabozantinib vs. cabozantinib + PD901), as compared with vehicle (black), and 1.5 mg/kg/d PD901 alone (gray). 
Vehicle and PD901 tumor responses are previously published historic controls adapted with permission from Cancer Discovery (11). (D) Waterfall plot of 
the change in tumor volume of mice treated with 12.3 mg/kg/d cabozantinib in combination with 1.5 mg/kg/d PD901 for 21 days. For both C and D, each 
bar represents an individual tumor-bearing mouse. The left y axis indicates the log2 of the fold change in volume over the indicated time relative to day 0 
measurements. The right y axis indicates the equivalent percentage change in tumor volume.
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is readily achieved in patients, the potential combined toxicity 
of these agents in humans still needs to be taken into account. 
However, the more important finding in this study is that selec-
tive MNK kinase inhibitors should be effective in NF1-mutant 
tumors, which would circumvent any toxicity associated with 
inhibiting other cabozantinib targets. Moreover, because MNK 
appears to be a fairly cancer-specific target, MNK inhibitors 
may have a unique therapeutic window. The discovery that 
MNK is the functional therapeutic target of cabozantinib in 
these tumors may be reminiscent of the finding that anaplastic 
lymphoma receptor tyrosine kinase (ALK) is the key target of 
the multikinase inhibitor crizotinib in lung cancer (25). Nota-
bly, the initial ALK/crizotinib discovery led to the development 
of more selective ALK inhibitors that appear to be more effec-
tive than crizotinib and can overcome crizotinib resistance (25). 
The recent emergence of more MNK-selective inhibitors may 
provide a unique opportunity for beginning clinical studies with 
these more specific agents from the onset. Finally, while these 
studies validate MNK as an important new therapeutic target in 
MPNSTs, this combination could also be examined in other Ras 
and/or mTOR-dependent cancers.
eIF4E is a known MNK target, and our phosphomimetic stud-
ies demonstrate that eIF4E dephosphorylation is an important 
mediator of the therapeutic response. However, MNK kinases 
have additional known and likely unknown substrates (reviewed 
in ref. 13). Some of these can be conceptually ruled out as contrib-
utors to the therapeutic response, such as Sprouty2, which would 
be expected to be destabilized by MNK inhibition (reviewed in ref. 
13). While it will be interesting to elucidate the complete thera-
peutic effects of MNK suppression, our studies suggest that eIF4E 
phosphorylation at serine 209 can serve as a useful biomarker to 
identify tumors in which MNK kinases are activated. Importantly, 
we find that MNK kinases are activated in a high percentage of 
primary human MPNSTs. A relatively homogenous activation of 
this pathway might be expected in tumors from patients with a 
familial cancer syndrome that overall exhibits less heterogeneity 
than sporadic cancers. However, eIF4E phosphorylation can be 
used to identify other tumor types or tumor subsets that might 
benefit from this therapeutic approach. Taken together, these 
studies demonstrate that combined suppression of MNK and 
MEK potently kills MPNSTs and have established a therapeutic 
paradigm for these untreatable malignancies.
Methods
Cell lines and reagents. S462s and IMR90s were purchased from 
ATCC. The 90-8TLs were provided by Eric Legius (Catholic Uni-
versity Leuven). CM261, CM173, 1A50, and 2629_C were gener-
ated from MPNSTs isolated from NPcis mice. All cell lines were 
maintained in DMEM supplemented with 10% FBS, penicillin/
streptomycin, and l-glutamine. Antibodies were obtained from 
the following sources: Cell Signaling Technologies: eIF4E (catalog 
9742), MNK1 (C4C1) (catalog 2195), p-Met (D26) (catalog 077), 
p-ERK1/2 (D13.14.4E) (catalog 4370), ERK1/2 (catalog 9102), pS6 
(catalog 2215), S6 (5G10) (catalog 2217), GAPDH (14C10) (catalog 
2118), 4E-BP1 (catalog 9452), and VEGFR2 (55B11) (catalog 2479); 
Invitrogen/Life Technologies: p-eIF4E (catalog 44528G); Sigma-
Aldrich: α-tubulin (B-5-1-2) (catalog T5168); R&D Systems: Axl 
MPNST cells and was potently inhibited in response to cabozan-
tinib. Moreover, combined cabozantinib/PD901 treatment pro-
moted cell death in mouse MPNST lines (Figure 5B). We there-
fore evaluated the therapeutic effects of cabozantinib/PD901 
in vivo. Genetically engineered mice harboring Nf1/p53 mutant 
MPNSTs were treated with cabozantinib at 12.3 mg/kg/d alone 
or in combination with 1.5 mg/kg PD901 daily. (Figure 5C). 
Similarly to in vitro observations, cabozantinib alone exerted 
cytostatic effects; however, when combined with PD901, every 
tumor regressed, shrinking between 36% and 63% (Figure 5C). 
We performed a second preclinical study, extending treatment 
for 21 days, and found that the tumor regression was main-
tained, which is particularly striking given that these tumors 
grow on average 4- to 7-fold and kill control mice in half of this 
time (Figure 5D). Together with the genetic analysis provided, 
these findings suggest that combined MEK/MNK inhibition 
represents a promising therapeutic strategy for treating NF1-
mutant MPNSTs. While, cabozantinib or other multikinase 
inhibitors that suppress MNK kinases could be evaluated in this 
therapeutic context in clinical trials, more importantly, these 
findings support the potential utility of selective MNK inhibitors 
for these and likely other cancers.
Discussion
MPNSTs are highly aggressive malignancies that develop in 
neurofibromatosis type 1 patients or can arise spontaneously 
(8). These tumors frequently metastasize, and there are cur-
rently no effective treatments for unresectable lesions, which 
are lethal in 70% of cases (9). Here, we identify what we believe 
is a new therapeutic target in MPNSTs and provide a promising 
therapeutic strategy for these deadly malignancies. Using a vari-
ety of genetic and chemical approaches, we show that suppres-
sion of MNK kinases effectively cooperates with MEK inhibitors 
to kill human MPNST cells. Moreover, we find that the multiki-
nase inhibitor cabozantinib directly inhibits MNK1 and MNK2 
and cooperates with MEK inhibitors to induce dramatic MPNST 
regression in vivo. Importantly, these therapeutic effects cannot 
be recapitulated by suppressing other cabozantinib targets and 
require the suppression of MNK-induced eIF4E phosphoryla-
tion. Together, these studies highlight the potential therapeutic 
utility of MNK kinase inhibitors in cancer and provide an impor-
tant clinical setting in which they should be evaluated. Notably, 
at least 2 phase I studies of more selective MNK inhibitors are 
currently underway (ClinicalTrials.gov eFT508, BAY 1143269).
Previous studies have shown that MNK is important for 
the development of PTEN-mutant cancers and that loss-of-
function mutations delay tumor formation in mouse models 
(17). However, not all genes that contribute to tumor develop-
ment are therapeutic targets. Here, we show that acute sup-
pression of MNK plays a causal role in mediating an effective 
therapeutic response when combined with MEK inhibitors. 
Moreover, we find that MNK is an unappreciated direct target 
of the FDA-approved drug cabozantinib, suggesting that tri-
als evaluating the combined effects of cabozantinib and MEK 
inhibitors should be considered. Notably, while we have found 
that a relatively low preclinical dose of cabozantinib is effec-
tive in this model when combined with a dose of PD901 that 
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reactions were run using a Bio-Rad iCycler iQ thermal cycler. Sam-
ples were run in triplicate, and expression levels were determined 
based on a standard curve run with each primer set; levels were nor-
malized to an internal control, GAPDH. The following are the prim-
er sequences used: GAPDH; for: 5′-CATGTTCGTCATGGGTGT-
GAACCA-3′, rev: 5′-ATGGCATGGACTGTGGTCATGAGT-3′ and 
MKNK2; for: 5′-AGCCGAACTTCAGGGTTTC-3′, rev: 5′-AAGT-
CAGAGTCTCCGTGGT-3′.
In vivo drug treatments and dosing schedule. C57BL/6-Trp53tm1Tyj 
Nf1tm1Tyj (NPcis) mice were bred and maintained as previously 
described (24). Mice were palpated to detect tumors starting at 2 
months of age, and treatment commenced when tumors reached 
200 to 1,000 mm3. Mice were treated daily with cabozantinib by oral 
gavage at 12.3 mg/kg. Cabozantinib was prepared in 65% D5W/30% 
propylene glycol/5% Tween-80 and was briefly vortexed followed 
by sonication for 2 minutes. PD901 was administered at 1.5 mg/kg 
once per day immediately prior to cabozantinib administration by 
oral gavage, and PD901 was prepared as previously described (27). 
To track changes in tumor volume, tumor size was measured at day 
0 and subsequently every 2 to 3 days by vernier calipers; volume was 
calculated using the standard formula L × W2 × 0.52.
Statistics. For quantitative measurements, graphs represent 
mean ± SD. Where indicated, data are presented as fold change or 
log2 fold change over initial measurements. Changes in tumor vol-
ume are presented in a waterfall plot with each bar representing 
the change in tumor volume of an individual animal in the study. 
ANOVA followed by Bonferroni’s multiple comparison tests, 2-tailed 
unpaired t tests, and Mann-Whitney U tests was used to compare 
data sets where indicated, and P values are shown. A P value less 
than or equal to 0.05 was considered significant. Data were graphed 
and analyzed using GraphPad Prism v.6.
Study approval. Animal procedures were approved by the Center 
for Animal and Comparative Medicine at Harvard Medical School in 
accordance with the NIH Guide for the Care and Use of Laboratory Ani-
mals (National Academies Press. 2011.) and the Animal Welfare Act. 
Consent was obtained for human tissue acquisition according to IRB-
approved protocol (S52563) and local ethical committees.
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(catalog AF154); and Covance: HA.11 (MMS-101P). INK128 was 
purchased from Active Biochem. CGP57380 and cercosporamide 
were purchased from Tocris Bioscience. PF04217903 was pur-
chased from Selleck Chemicals. Cabozantinib was purchased from 
ChemieTek. PD901 was a gift from Kevin Shannon (UCSF, San 
Francisco, California, USA).
Human MPNST samples. All patients were diagnosed as having neu-
rofibromatosis type 1.
RNAi. pLKO.1 lentiviral expression plasmids containing 
shRNAs against eIF4E (human and mouse) and MNK2 were 
obtained from the Broad RNAi Consortium. The target sequenc-
es for hairpins directed against human eIF4E were as follows: 
shEIF4E_1 (TRCN0000062574): CCAAAGATAGTGATTGGTTAT; 
and shEIF4E_2 (TRCN0000299576): CCGACTACAGAAGAG-
GAGAAA. The target sequences for hairpins directed against mouse 
eIF4E were as follows: shEIF4E_3 (TRCN0000077475): CCGAA-
GATAGTGATTGGTTAT; and shEIF4E_4 (TRCN0000077477): 
CGATTGATCTCTAAGTTTGAT. The target sequence for hairpins 
directed against human MNK2 is shMNK2 (TRCN0000342285): 
CGCCGTCAAGATCATTGAGAA. Nontargeting, siMNK1, siAXL, 
and siKDR pools were purchased from Dharmacon (D-001810-10, 
L-004879-00, L-003104-00, and L-003148-00, respectively). 
siRNAs were transfected into cells using RNAiMax lipofectamine 
reagent from Invitrogen.
Soft agar, cellular proliferation, and cell death studies. For soft 
agar experiments, 50,000 S462 cells or 25,000 CM173 cells were 
suspended in 0.35% agar in growth media on top of 0.5% agar in 
growth media in 6-well plates. After 3 weeks, colonies were fixed 
and stained with crystal violet; plates were scanned and the number 
of colonies per well was determined using ImageJ software (NIH). 
For cellular proliferation and cell death assays, 150,000 cells per 
well were seeded in 6-well plates, and approximately 24 hours after 
plating, day 0 counts were taken. For inhibitor experiments, drug 
treatments were started on day 0, and for siRNA experiments, cells 
were transfected approximately 24 hours before plating. All S462 
cell death assays were performed in DMEM with 2% FBS starting on 
day 0. Final cell counts were taken at 72 or 96 hours where indicated 
to determine changes in cell number from day 0. For Western blots 
to determine drug efficacy or efficient knockdown, lysates were col-
lected 24 hours following the addition of inhibitors.
eIF4E constructs. pHA-eIF4E was a gift from Dong-Er Zhang 
(UCSD, La Jolla, California, USA) (Addgene plasmid catalog 17343). 
The S209D and wobble mutations were generated via site-directed 
mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit, Strat-
agene). WT and mutant cDNAs were subsequently cloned into the 
pHAGE-Flag-HA mammalian lentiviral expression vector.
Binding constant measurements and calculations. Binding of 
epitope-tagged MNK1 and MNK2 to immobilized ligand was measured 
as a function of unlinked test compound concentration using meth-
ods described previously (26). Cabozantinib dose-response curves 
were graphed using nonlinear least-square fit with the Levenberg- 
Marquardt algorithm. Determining kd based on the dose response 
curves used the Hill equation with the Hill slope set to –1.
qPCR. RNA was isolated using QIAGEN RNeasy kit. 50 ng of 
total RNA was used for each reaction, and cDNA synthesis and PCR 
amplification were performed using the qScript One-Step SYBR 
Green Kit for iQ (Quanta Biosciences). Quantitative PCR (qPCR) 
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